Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NHKC-1 (valsartan + levamlodipine) vs levamlodipine in primary hypertension
CTR20243322Phase 3Completed
- Sponsor
- Sunshine Novo
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of valsartan + levamlodipine in essential hypertension (4 arms), sponsored by Sunshine Novo. Primary endpoint: Change in clinic seated systolic blood pressure at week 8. Started Sep 2024; status: completed.
02
Drugs
valsartan + levamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20243322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243322.